How We Ranked the Best Prescription Dry Eye Meds for 2026
The prescription dry eye landscape in 2026 looks very different than it did even three years ago. Brand-name Restasis® still costs $500 to $700 a month at retail pharmacies. Xiidra® can run $600 a month or more. GoodRx introduced a paid Companion membership that gates the lowest advertised prices. The FDA-approved authorized generic of Restasis® arrived in 2022, but most retail pharmacies still don't stock it specifically. A wave of new telehealth services has changed how patients access these drugs entirely — some legitimately, some with international sourcing patients aren't told about until they've already paid.
To rank the 5 best prescription dry eye options for 2026, our editors looked at four factors that actually matter for the patient: total monthly cost (including hidden fees, memberships, and shipping), medication sourcing (who manufactured it and where), convenience (does it include the doctor visit, and how fast does it ship), and transparency (does the patient know what they're getting before they pay).
Brand-name Restasis® remains the most clinically documented prescription dry eye drug in the U.S., on the market since 2003 and still the gold standard reference. But the brand-name price reflects two decades of patent protection, not what the medication actually costs to produce. Patients who don't have insurance covering Restasis®, or whose Medicare Part D plan has dropped it, are now choosing alternatives that deliver the same active ingredient at a fraction of the cost.
The single most important development for 2026 is the wider availability of the authorized generic of Restasis® — same active ingredient, same inactive ingredients, manufactured by Allergan in the same Waco, Texas facility as the brand-name version, dispensed at a small fraction of the brand-name price. Telehealth services that specifically dispense the authorized generic are the most reliable way to access it.
Xiidra® remains the leading non-cyclosporine alternative for patients who can't tolerate or don't respond to Restasis®, but it has no FDA-approved generic, no telehealth-friendly price option, and a documented taste-related side effect that affects roughly 1 in 5 users per the FDA prescribing information. It earned its spot in our ranking, but it sits below the cyclosporine options on total value.
What's New for Prescription Dry Eye in 2026
Three meaningful shifts have reshaped the prescription dry eye landscape in 2026 — and they're the reason this year's ranking looks different from previous years.
- The authorized generic of Restasis® is now widely accessible through telehealth. When the authorized generic first hit the market in 2022, distribution was limited and most retail pharmacies stocked unbranded cyclosporine generics from other manufacturers instead. By 2026, U.S.-based telehealth services have made the authorized generic specifically — manufactured by Allergan in Waco, Texas — available as a flat monthly subscription that includes the doctor visit and shipping. This is the single biggest reason brand-name retail Restasis® no longer makes financial sense for most uninsured or underinsured patients.
- GoodRx introduced the paid Companion membership tier. The advertised lowest prices on GoodRx for cyclosporine now typically require a $14.99/month Companion membership that auto-bills after a 7-day trial. Without the membership, the same prescription can cost $176 at one major pharmacy and $599 at another — same drug, same dose. Patients who relied on GoodRx in previous years now need to factor in the recurring membership fee when comparing total cost.
- International telehealth services have expanded into the U.S. market. Some services now offer cyclosporine 0.05% with medication sourced from international pharmacies — typically shipped from Turkey or India — with delivery windows of 2 to 4 weeks. These services can be cheaper than retail Restasis®, but they're generally more expensive than U.S.-based telehealth alternatives once doctor fees and shipping are factored in, and the international sourcing is a tradeoff patients deserve to know about up front.
Editor's Picks: Which Med Fits Your Situation
If you have insurance that fully covers brand-name Restasis®: stick with retail pharmacy and your insurance. Brand-name remains the reference standard with the longest clinical track record, and a low copay is hard to beat. Don't switch unless your coverage changes.
If you have an active Restasis® prescription and good local pharmacy options: GoodRx with the paid Companion membership can lower the price meaningfully — but only at certain pharmacies, and you won't know which generic you're getting until you pick it up. Works best for patients who don't mind hands-on pharmacy management.
If your doctor specifically prescribed Xiidra®: there's no generic alternative and no cheaper telehealth path for this specific drug. Retail pharmacy with your insurance is the only realistic option. If the taste side effect becomes a problem, talk to your doctor about switching to cyclosporine.
If you don't have insurance, are on Medicare with poor Restasis® coverage, or just want one flat monthly price that covers everything: U.S.-based telehealth with the authorized generic of Restasis® is the editor's top pick for 2026. Rain Eyecare is the only service in our comparison that dispenses the authorized generic specifically — manufactured by Allergan in Waco, Texas — at a flat $99/month that includes the online doctor visit, the prescription, free shipping, and a free bottle of Rain moisturizing eye drops with every refill.
